Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Apr 3;20(1):119.
doi: 10.1186/s12882-019-1297-y.

Serum klotho is inversely associated with metabolic syndrome in chronic kidney disease: results from the KNOW-CKD study

Hyo Jin Kim  1 , Joongyub Lee  2   3 , Dong-Wan Chae  4 , Kyu-Beck Lee  5 , Su Ah Sung  6 , Tae-Hyun Yoo  7 , Seung Hyeok Han  7 , Curie Ahn  8 , Kook-Hwan Oh  9
Affiliations
Observational Study

Serum klotho is inversely associated with metabolic syndrome in chronic kidney disease: results from the KNOW-CKD study

Hyo Jin Kim et al. BMC Nephrol. .

Abstract

Background: Metabolic syndrome (MS) is prevalent in chronic kidney disease (CKD). Klotho, a protein linked to aging, is closely associated with CKD. Each component of MS and klotho has an association. However, little is known about the association between klotho and MS per se. We investigated the association between serum klotho levels and MS using baseline cross-sectional data obtained from a large Korean CKD cohort.

Methods: Of the 2238 subjects recruited in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) between 2011 and 2016, 484 patients with missing data on serum klotho and extreme klotho values (values lower than the detectable range or > 6000 pg/mL) or with autosomal dominant polycystic kidney disease patients were excluded. The data of the remaining 1754 subjects were included in the present study. MS was defined using the revised National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria. Serum klotho levels were measured using an enzyme-linked immunosorbent assay.

Results: Mean patient age was 54.9 ± 12.1 years and 1110 (63.3%) were male. The prevalence of MS among all study subjects was 63.7% (n = 1118). The median serum klotho level was 527 pg/mL (interquartile range [IQR]: 418-656 pg/mL). Serum klotho level was significantly lower in MS patients than patients without MS (Median [IQR]; 521 pg/mL [413, 651] vs. 541 pg/mL [427, 676], respectively; P = 0.012). After adjusting for age, sex, estimated glomerular filtration rate, and overt proteinuria, serum klotho was independently associated with MS (adjusted odds ratio [OR], 0.44; 95% confidence interval, 0.23-0.82; P = 0.010). Furthermore, the adjusted OR for MS was found to be significantly increased at serum klotho levels of < 518 pg/mL (receiver operating characteristic curve cut-off value).

Conclusions: Serum klotho was inversely associated with the presence of MS in patients with CKD.

Trial registration: This trial was registered on ClinicalTrials.gov on 26 June 2012 ( https://clinicaltrials.gov;NCT01630486 ).

Keywords: Chronic kidney disease; Klotho; Metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study protocol was approved by the ethical committee of each participating clinical center, including the Institutional Review Boards of Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Medical Center, Seoul St. Mary’s Hospital, Gil Hospital, Eulji General Hospital, Chonnam National University Hospital, and Busan Paik Hospital. All participating patients provided written informed consent. The study protocol was in accordance with the principles of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Prevalence of the metabolic syndrome and components of metabolic syndrome in the study subjects. Sixty four percent of patients had MS. Of the components of MS, high blood pressure (95.8%) was the most common, followed by high fasting glucose (63.7%) and abdominal obesity (53.8%). MS, metabolic syndrome; HDL, high-density lipoprotein
Fig. 2
Fig. 2
Prevalence of metabolic syndrome across CKD stages. The prevalence of MS was > 50% even for early stage CKD. The prevalence of MS was higher in advanced stages of CKD (P < 0.001). MS, metabolic syndrome
Fig. 3
Fig. 3
Multivariable-adjusted odds ratios of metabolic syndrome according to levels of estimated glomerular filtration rate. An eGFR of 60 ml/min/1.73m2, as a reference value of decreased renal function, was taken as the reference point (OR = 1.00). The adjusted OR of MS was significantly increased at eGFR levels of < 60 ml/min/1.73m2. The model was adjusted for age, sex, eGFR, and overt proteinuria. The solid line represents the multivariable-adjusted ORs of MS according to levels of eGFR. The dashed lines indicate 95% confidence intervals. eGFR, estimated glomerular filtration rate; OR, odds ratio; MS, metabolic syndrome
Fig. 4
Fig. 4
Serum klotho level according to metabolic syndrome and numbers of metabolic syndrome components. a Serum klotho was significantly lower in MS patients compared with patients without MS (median [interquartile range]; 521 pg/mL [413, 651] vs. 541 pg/mL [427, 676], respectively; P = 0.012). b Klotho levels tended to decrease as numbers of MS components increased (P = 0.038). MS, metabolic syndrome
Fig. 5
Fig. 5
Serum klotho levels across CKD stages. Advanced CKD stages were associated with lower serum klotho levels (P < 0.001). CKD, chronic kidney disease
Fig. 6
Fig. 6
Multivariable-adjusted odds ratio of metabolic syndrome according to levels of serum klotho. A serum klotho level of 518 pg/mL (ROC curve cut-off value) was taken as the reference point (OR = 1.00). The adjusted OR of MS was significantly increased at serum klotho levels of < 518 pg/mL. The model was adjusted for age, sex, eGFR, and overt proteinuria. The solid line represents the multivariable-adjusted ORs of MS according to levels of eGFR. The dashed lines indicate 95% confidence intervals. Overt proteinuria, 24-hour urine protein > 500 mg/day; ROC, receiver operating characteristic; eGFR, estimated glomerular filtration rate; OR, odds ratio; MS, metabolic syndrome
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–1077. doi: 10.1093/aje/kwf145. - DOI - PubMed
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. - DOI - PubMed
    1. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–2373. doi: 10.2215/CJN.02180311. - DOI - PMC - PubMed
    1. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140. doi: 10.1681/ASN.2005010106. - DOI - PubMed
    1. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421–435. doi: 10.2147/DMSO.S45183. - DOI - PMC - PubMed

Publication types

Associated data